Medistem’s management is focused on developing products using the Endometrial Regenerative Cell (ERC) to help sufferers of critical limb ischemia, ischemic heart disease and other conditions that could benefit from the growth of new blood vessels. Additionally, Medistem continues to believe strongly in basic scientific research and the value of peer reviewed publications. Together with its extensive collaborator network of leading scientists, Medistem has jointly published over 20 articles in peer-reviewed journals, pushing the forefront of stem cell discovery and application. Medistem believes that such research not only expands its intellectual property portfolio but also establishes its reputation in the field and advances the stem cell industry as a whole.
To learn more about MediStem’s Technologies, use the links below.
- Intellectual Property
- Product Pipeline